Phuturdex › Diseases › Hematologic Diseases
Drugs in development · updated 30 October 2026
Hematologic Diseases: drugs in development
As of 30 October 2026 there are 48 active clinical trials (recruiting or ongoing, phases I–III) on 57 drugs for hematologic Diseases. 19 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Mezagitamab | III | 2 | NCT06948318 |
| ASTX030 | II–III | 1 | NCT04256317 |
| Etavopivat | III | 1 | NCT04624659 |
| QTX-2101 | III | 1 | NCT07504458 |
| Bezuclastinib TabletsCGT9486 | II | 2 | NCT05186753 |
| ATV-1601 | I–II | 1 | NCT07601425 |
| DibotatugDR-01 | I–II | 1 | NCT07712562 |
| EDIT-301 | I–II | 1 | NCT04853576 |
| Epetraborole | II | 1 | NCT07891533 |
| Golidocitinib | II | 1 | NCT07303881 |
| Itacitinib | II | 1 | NCT04859946 |
| Senicapoc | II | 1 | NCT07282210 |
| SemustineMe-CCNU | I | 2 | NCT06809712 |
| CD19 | I | 1 | NCT04806347 |
| CK0804 | I | 1 | NCT05423691 |
| KLN-1010 | I | 1 | NCT07075185 |
| OriCAR-017 | I | 1 | NCT06271252 |
| PMD-026 | I | 1 | NCT07379125 |
| VIP943 | I | 1 | NCT06034275 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PirtobrutinibJaypirca® | III | 5 | NCT05023980 |
| CTX001 | III | 4 | NCT04208529 |
| RituximabRuxience, Rituxan | III | 3 | NCT05023980 |
| BendamustineBendamustin, Bedamustine | III | 2 | NCT05023980 |
| CrizanlizumabAdakveo® | III | 2 | NCT06439082 |
| IbrutinibPCI 32765, Imbruvica® | III | 2 | NCT04662255 |
| LenalidomideRevlimid, lenalinomide | III | 2 | NCT05317416 |
| MitapivatAG-348, Pyrukynd® | III | 2 | NCT05144256 |
| VenetoclaxVentoclax, Venclexta® | II–III | 2 | NCT04256317 |
| AcalabrutinibACP-196, Calquence® | III | 1 | NCT04662255 |
| All-trans retinoic acidATRA, Tretinoin | III | 1 | NCT07504458 |
| Arsenic TrioxideTrisenox®, Arsenic trioxide Accord® | III | 1 | NCT07504458 |
| AzacitidineAzacytidine, 5-azacytidine | II–III | 1 | NCT04256317 |
| CedazuridineCedaruridine | II–III | 1 | NCT04256317 |
| ElranatamabElrantamab, Elrexfio® | III | 1 | NCT05317416 |
Sorted by most advanced phase and number of active trials. Showing 15 of 38 drugs.
All 57 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Acute myeloid leukemia 314 drugs
- Multiple myeloma 272 drugs
- Myelodysplastic Syndromes 203 drugs
- Chronic lymphocytic leukemia 137 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Hematologic neoplasm 216 drugs
- Leukemia 153 drugs
- Non-Hodgkin lymphoma 269 drugs
- Lymphoma 252 drugs
- Myelofibrosis 91 drugs
- Sickle-cell disease 73 drugs
- Myeloproliferative disorders 91 drugs
Broader categories
- Neoplasm 671 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Immunoproliferative disorder 16 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Lymphatic system disease 20 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D006402 “Hematologic Diseases”.